AI Article Synopsis
- Researchers evaluated two multiplex immunoassays for measuring adiponectin, resistin, ghrelin, and leptin, comparing them to traditional ELISA assays.
- The correlation between multiplex and ELISA results was strong (r > 0.9), indicating good agreement, although notable differences in analytical levels were observed.
- Both assays showed similar levels of variation, with a coefficient of variation ≤15%, suggesting multiplex assays are valid alternatives to ELISA, but results may not be directly interchangeable.
Article Abstract
Background: Many different multiplex biomarker immunoassays based on Luminex®-technology have been developed during recent years. We have evaluated the performance of two multiplex immunoassays for determination of adiponectin, resistin, ghrelin and leptin in comparison to corresponding, conventional ELISA assays.
Methods: Human serum or plasma samples were analysed by commercially available multiplex and ELISA immunoassays manufactured by Millipore Corp.
Results: The correlation between tested multiplex and ELISA immunoassays was good, r > 0.9 for all analytes. The agreement between the methods was acceptable but there were differences in analytical levels. Intra- and inter-assay variation was comparable between both assays. The coefficient of variation for all analytes, independent of method, was ≤15% and for most of them <10%.
Conclusion: The performance of the tested multiplex assays was reasonable and they can be considered as valid options to the conventional ELISA assays. However, results obtained with the two different techniques are not necessarily interchangeable due to differences in the concentration levels.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365513.2011.554996 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Three blood-based biomarkers of neurological injury-glial fibrillary acidic protein (GFAP), neurofilament light (Nf-L), and Tau-have emerged as promising biomarkers of neurological disorders and injuries such as hypoxic-ischemic encephalopathy (HIE), traumatic brain injury, and Alzheimer's disease (AD). The low levels of GFAP, Nf-L, and Tau in serum and plasma require highly sensitive assays to detect them. Here, we report the analytical validation of an ultrasensitive, electrochemiluminescence-based, multiplexed immunoassay for neurological biomarker assessment.
View Article and Find Full Text PDFBackground: Insulin-like Growth Factor-1 (IGF-1) and its receptor (IGF-1R) are known to play a role in biological aging. Several studies have explored the correlation between serum levels of IGF-1 and Alzheimer's-related dementia (AD). However, conflicting reports exist regarding whether elevated or reduced IGF-1 levels increase the risk of AD.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Gothenburg, Sweden.
Background: Recently, the development of ultra-sensitive immunoassays has allowed for the detection, in blood, of proteins related to the pathophysiology of Alzheimer's disease (AD), with phosphorylated tau (p-tau) being the most promising. However, current methods are often limited by their ability to measure one analyte, lacking the potential for discovery and inclusion of additional biomarkers with supplemental value. In this pilot study, we explored proteomic changes using the novel NUcleic acid Linked Immuno-Sandwich Assay (NULISA™) platform, focusing on patients with mild cognitive impairment (MCI).
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Background: Alzheimer's disease (AD) is a multifaceted condition associated with various brain pathologies, necessitating diverse biomarkers for precise prognosis, diagnosis, clinical management, and therapeutic development/evaluation. The integration of multiple biomarkers into a single test can enhance efficiency, reduce analytical errors, and save on specimen volume. Alamar Biosciences recently introduced the NULISAseq CNS disease panel, a multiplex NUcleic acid-linked Immuno-Sandwich Assay (NULISA) targeting ∼120 analytes.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin - Institute of Psychiatry and Psychotherapy, Berlin, Berlin, Germany.
Background: Mechanisms of cellular senescence affecting neuroimmune responses, homeostasis, and synaptic functioning associate with core Alzheimer's disease (AD) biomarkers, i.e., pathological aggregation of β-amyloid (Aβ) and tau protein, while their longitudinal associations remain unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!